Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) announced that its Board of Directors has authorized a stock buyback plan on Monday, November 16th, RTT News reports. The company plans to buy back $54.95 million in shares. This repurchase authorization permits the biotechnology company to reacquire up to 2.5% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its shares are undervalued.
Lakefront Biotherapeutics American Depositary Shares Trading Up 2.4%
LKFT traded up $0.81 on Monday, reaching $34.79. The company had a trading volume of 292,601 shares, compared to its average volume of 265,015. The company has a fifty day moving average of $30.49 and a 200-day moving average of $29.94. The company has a market capitalization of $2.29 billion, a P/E ratio of -24.67 and a beta of 0.22. Lakefront Biotherapeutics American Depositary Shares has a one year low of $25.68 and a one year high of $36.24.
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) last released its earnings results on Wednesday, November 11th. The biotechnology company reported ($0.05) EPS for the quarter. The business had revenue of $7.87 million for the quarter. Research analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -1.46 EPS for the current year.
Analysts Set New Price Targets
A number of research firms have issued reports on LKFT. Weiss Ratings raised shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, October 2nd. Morgan Stanley upped their target price on shares of Lakefront Biotherapeutics American Depositary Shares from $26.00 to $27.00 and gave the stock an “equal weight” rating in a research report on Monday. Raymond James Financial restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Thursday. UBS Group raised Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a report on Wednesday, September 23rd. Finally, Royal Bank Of Canada raised Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $26.00 to $45.00 in a report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $36.00.
Check Out Our Latest Report on Lakefront Biotherapeutics American Depositary Shares
Top Lakefront Biotherapeutics American Depositary Shares Stories
Here are a few of the latest stories about LKFT:
- Positive Sentiment: Lakefront launched a new buyback of up to €50 million after completing its previous €50 million program. The company says it may repurchase up to 2.5% of its shares, a move that can signal management confidence and support demand for the stock. Lakefront Initiates New €50 Million Share Repurchase Program
- Positive Sentiment: TD Cowen initiated coverage with a “strong buy” rating, adding a bullish analyst view. TD Cowen coverage reported by Zacks
- Negative Sentiment: Morgan Stanley raised its price target from $26 to $27 but kept an “equal weight” rating. The target remains about 22.4% below the cited share price, suggesting the firm sees downside from current levels.
Lakefront Biotherapeutics American Depositary Shares Company Profile
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Lakefront Biotherapeutics American Depositary Shares
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Lakefront Biotherapeutics American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakefront Biotherapeutics American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
